C4 Therapeutics Inc. has released a corporate presentation detailing advancements in their portfolio of degrader medicines aimed at transforming patient lives through targeted protein degradation. The presentation highlights the company's work in designing orally bioavailable degraders, with a focus on multiple myeloma and collaborations with leading global pharmaceutical companies. It also discusses the decision not to advance CFT1946 beyond Phase 1 trials and plans to seek partnerships for the BRAF program. Additionally, there is a mention of a license and collaboration agreement with Betta Pharmaceuticals for activities in Greater China. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.